Anna C. Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna C. Jacobs has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- George Risi
Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC 20024, USA
1 shared publication - Lynn Khosrowshahi
Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC 20024, USA
1 shared publication - Mark T. Albrecht
Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC 20024, USA
1 shared publication - Philip M. Polgreen
University of Iowa
1 shared publication - Susan E. Beekmann
Division of Infectious Diseases, Carver College of Medicine University of Iowa , Iowa City, Iowa
1 shared publication the COVID-19 Study Team
1 shared publication
Latest Publications
- Open Access
Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
The SARS-CoV-2 pandemic has had a significant impact on the United States healthcare system. This is exacerbated by antimicrobial-resistant bacterial pathogens endemic to healthcare settings. Respiratory viral infections are known to predispose patients to bacterial infections, which were a major contributor to mortality in previous pandemics. This study’s goal was to gain an understanding of bacterial infections in hospitalized COVID-19 patients. A case form for COVID-19 patients with bacterial infections was developed and sent to clinicians on the Emerging Infections Network listserv. The case form included 22 questions on patient demographics, COVID-19 and bacterial infection and treatment, and patient outcome. One hundred and nine patient cases were collected and analyzed. The majority of patients (59.6%) were critically ill, and 66.9% of patients were diagnosed with sepsis. Empiric and directed antibiotics were administered to 81.6% and 94.5% of patients, respectively. Thirty-one infections were not resolved with antibiotics, and of those patients, 74.2% died. Unresolved bacterial infections were found to be a significant contributor to mortality in this case series. These bacterial infections can most likely be attributed to long hospital stays and exposure to nosocomial pathogens. Thus, unresolved nosocomial bacterial infections warrant additional attention during future events where there is a strain on the US healthcare system.
Open AccessImpact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey
The SARS-CoV-2 pandemic has had a significant impact on the United States healthcare system. This is exacerbated by antimicrobial-resistant bacterial pathogens endemic to healthcare settings. Respiratory viral infections are known to predispose patients to bacterial infections, which were a major contributor to mortality in previous pandemics. This study’s goal was to gain an understanding of bacterial infections in hospitalized COVID-19 patients. A case form for COVID-19 patients with bacterial infections was developed and sent to clinicians on the Emerging Infections Network listserv. The case form included 22 questions on patient demographics, COVID-19 and bacterial infection and treatment, and patient outcome. One hundred and nine patient cases were collected and analyzed. The majority of patients (59.6%) were critically ill, and 66.9% of patients were diagnosed with sepsis. Empiric and directed antibiotics were administered to 81.6% and 94.5% of patients, respectively. Thirty-one infections were not resolved with antibiotics, and of those patients, 74.2% died. Unresolved bacterial infections were found to be a significant contributor to mortality in this case series. These bacterial infections can most likely be attributed to long hospital stays and exposure to nosocomial pathogens. Thus, unresolved nosocomial bacterial infections warrant additional attention during future events where there is a strain on the US healthcare system.